CRISPR/$CRSP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CRISPR
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Ticker
$CRSP
Sector
Primary listing
Industry
Biotechnology
Headquarters
Zug, Switzerland
Employees
393
ISIN
CH0334081137
Website
CRISPR Metrics
BasicAdvanced
$5.5B
-
-$4.52
1.87
-
Price and volume
Market cap
$5.5B
Beta
1.87
52-week high
$63.68
52-week low
$30.04
Average daily volume
3.3M
Financial strength
Current ratio
15.635
Quick ratio
15.532
Long term debt to equity
11.035
Total debt to equity
11.992
Profitability
EBITDA (TTM)
-455.241
Gross margin (TTM)
-1,061.93%
Net profit margin (TTM)
-1,023.64%
Operating margin (TTM)
-1,259.20%
Effective tax rate (TTM)
-1.04%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-12.88%
Return on equity (TTM)
-19.71%
Valuation
Price to revenue (TTM)
136.179
Price to book
2.84
Price to tangible book (TTM)
2.84
Price to free cash flow (TTM)
-16.665
Free cash flow yield (TTM)
-6.00%
Free cash flow per share (TTM)
-360.51%
Growth
Revenue change (TTM)
-86.13%
Earnings per share change (TTM)
65.78%
3-year revenue growth (CAGR)
-65.47%
3-year earnings per share growth (CAGR)
5.38%
What the Analysts think about CRISPR
Analyst ratings (Buy, Hold, Sell) for CRISPR stock.
Bulls say / Bears say
CRISPR Therapeutics' lead product, Casgevy, received FDA approval in December 2023 for treating sickle cell disease and beta-thalassemia, marking the first approval of a CRISPR-based gene-editing therapy. This milestone positions the company at the forefront of gene-editing treatments, potentially opening significant market opportunities. (Nasdaq)
The company's in vivo editing programs, including CTX310 and CTX320, aim to edit genes directly within the body, potentially offering more accessible and scalable treatments compared to ex vivo approaches. Success in these programs could dramatically expand the range of treatable diseases and patient populations. (Investing.com)
Strategic partnerships with industry leaders like Vertex Pharmaceuticals, Nkarta, and Capsida Biotherapeutics enhance CRISPR Therapeutics' research capabilities and expand its therapeutic portfolio, bolstering its position in the biotech sector. (DirectorsTalk Interviews)
Despite the approval of Casgevy, CRISPR Therapeutics has reported significant operating losses, with a net loss of $150.7 million in 2023, indicating ongoing financial challenges. (The Motley Fool)
The company faces intense competition from other gene-editing firms, such as Editas Medicine and Beam Therapeutics, which are developing similar therapies for sickle cell disease and beta-thalassemia, potentially impacting CRISPR's market share. (Nasdaq)
CRISPR Therapeutics' stock has experienced volatility, with a 34% decline over the past year, reflecting investor concerns over commercialization challenges and financial sustainability. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CRISPR Financial Performance
Revenues and expenses
CRISPR Earnings Performance
Company profitability
CRISPR News
AllArticlesVideos
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
GlobeNewsWire·2 weeks ago
Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million?
24/7 Wall Street·4 weeks ago
Biotech Stock for Options Bears to Target Right Now
Schaeffers Research·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CRISPR stock?
CRISPR (CRSP) has a market cap of $5.5B as of July 10, 2025.
What is the P/E ratio for CRISPR stock?
The price to earnings (P/E) ratio for CRISPR (CRSP) stock is 0 as of July 10, 2025.
Does CRISPR stock pay dividends?
No, CRISPR (CRSP) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next CRISPR dividend payment date?
CRISPR (CRSP) stock does not pay dividends to its shareholders.
What is the beta indicator for CRISPR?
CRISPR (CRSP) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.